Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Specimen Handling 280Magnetic Resonance Spectroscopy 233pembrolizumab 220Carboplatin 180Cisplatin 146Biopsy 146Cyclophosphamide 138Paclitaxel 128Nivolumab 118Bevacizumab 106Gemcitabine 105Radiotherapy 90Dexamethasone 83Pemetrexed 79fludarabine 74Docetaxel 74atezolizumab 73Fluorouracil 73Doxorubicin 73Radiation 72Leucovorin 68Rituximab 66Oxaliplatin 64venetoclax 60Prednisone 60durvalumab 58Cetuximab 56Vincristine 55Etoposide 54Lenalidomide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
KP 1339 × 30 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡